EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 9
Issue: 11
101-109
Year: 2022

DETAILS OF OSTEOPOROSIS

Ajay Sabale*[1], Mrunalini Unecha[2], Prof. Santosh Waghmare[3], Prof. Andhle A.K.[3] and Dr. Hemant Kamble[4]

[1]Student, Department of Pharmacology, [2]Student, Department of Pharmaceutics, [3]Professor, Department of Pharmacy, [4]Principle, Department of Pharmacy.
[1,2,3,4]Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharate, Shirur, Pune, Maharashtra.

***Corresponding Author: Ajay Sabale**
Student, Department of Pharmacology, Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharate, Shirur, Pune, Maharashtra.

Article Received on 28/08/2022 **Article Revised on 18/09/2022** **Article Accepted on 08/10/2022**

ABSTRACT
Foundation: Osteoporosis is the most well-known constant metabolic bone illness. It has been assessed that in excess of 10 million individuals in the US and 200 million people overall have osteoporosis. Considering that the maturing populace is quickly expanding in numerous nations, osteoporosis could turn into a worldwide test with an effect on the personal satisfaction of the impacted people. Osteoporosis can be characterized as a condition described by low bone density and expanded hazard of fractures because of the disintegration of the bone engineering. A comprehensive multidisciplinary approach to treating osteoporosis includes therapies like calcium and vitamin D, bisphosphonates, oestrogen, selective oestrogen receptor modulators, calcitonin, parathyroid hormone, balance and exercise training programs, and the minimally invasive spine procedures vertebroplasty and kyphoplasty. Here we examine the molecular basis of bone remodeling and the aetiology of osteoporosis, show the pharmacological choices that are currently available, and talk about upcoming therapeutics that target novel mechanisms, investigational medications, and novel prospective therapeutic approaches.

1.0. INTRODUCTION
Osteoporosis happens because of an imbalance within bone resorption and bone development. Thus, bone breakdown surpasses bone arrangement. In the year 1993, the World Health Organization (WHO) characterized osteoporosis as a "progressive systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture[1-3]". Osteoporosis is an exceptionally pervasive problem assessed to influence 200 million ladies and men around the world, dominatingly those beyond 60 years old years.[4] Then again, more than 8.9 million fractures are brought about by osteoporosis yearly, and that implies that an osteoporotic crack happens at regular intervals. Roughly 33% of patients experience a hip break and, soon after, the crack, up to 20% bite the dust, predominantly because of prior conditions.[5] Patients who have one osteoporotic crack are at expanded risk for having another osteoporotic break create. For instance, the presence of at least one vertebral crack brings about a fivefold expanded hazard of having another vertebral break create.[6] The lifetime chance of breaks of the hip, wrist, and spine is 40%. The lifetime chance of hip break for a lady is 14%, and risk increments with age. At 80 years, 20% of ladies will have a hip break, and at 90 years, roughly half of ladies will have a hip crack. Ladies who are more seasoned than 85 years are roughly multiple times more probable than ladies 65-74 years to be owned up to the medical clinic for a hip break. Also, there is expanded dismalness and mortality for patients with osteoporosis, which will be talked about later. These mind-boggling measurements warrant satisfactory doctor and patient acknowledgment.

1.1. Normal Bone
Bone homeostasis, a living tissue[7], is kept up with by the osteoclast, which is liable for bone resorption, and the osteoblast, which is liable for bone development. Expanded bone resorption or diminished bone arrangement might bring about osteoporosis. Top bone mass is reached at the age of 25-30 years in ladies. In men, there is a sluggish decline of bone mineral density (BMD). In ladies, there is sped up deficiency of bone during the perimenopausal period, with easing back of the pace of misfortune quite a long while after menopause. By the age of 60 years, ladies and men have equivalent paces of bone misfortune, with sped up loss of complete bone mass at 80 years old years. As one ages, there are antagonistic consequences for bone quality, including sped up osteocyte demise, expanded bone turnover, diminished trabeculae, diminished cortical width, and expanded cortical porosity. The strength of the bone is connected with the bone mass, the appropriation of the mass, and the nature of the bone.

1.2 Osteoporotic Bone

Osteoporosis is portrayed by low bone mass, microarchitectural weakening of bone tissue prompting upgraded bone delicacy, and expanded fracture risk. The World Health Organization[8] has characterized osteoporosis based on BMD estimations got on dual energy x-ray absorptiometry (DEXA) as a T-score of more noteworthy than 2.5 standard deviations beneath the mean for ordinary, who are youthful people at their pinnacle bone mass. A low BMD is related with expanded fracture risk.[9] Low bone density might be optional to inability to accomplish ideal bone mass, bone misfortune brought about by expanded bone resorption, and deficient substitution of lost bone because of diminished bone arrangement.

1.3 Nature of Osteoporosis

Osteoporosis is characterized as a bone mineral density (BMD) having T score of - 2.5 or low, as per the demonstrative models delivered by WHO utilizing standard deviation scores of BMD connected with top bone mass in healthy ladies. BMD T scores between - 1 and - 2.5 are considered osteopenia and low bone mass.[10] Notwithstanding, BMD is only one of the gamble factors for break, and most of delicacy cracks happen in people with BMD T values over the - 2.5 edge, recommending that BMD is a restricted sign of osteoporosis in the center.[11,12] Disintegration of bone engineering expands the risk of crack. Osteoporotic fractures are the essential driver of bone-related morbidities and lead to a 2-8-crease expanded hazard of mortality.[13,14] For example, an 8-36% expanded mortality risk was found in no less than one year after a hip crack.[15] Fractures in the populace impacted by osteoporosis decide the personal satisfaction, as they cause torment, hindered versatility, considerably decrease pneumonic capability[16], influence the risk of disease, lead to changes in self-perception, psychosocial trouble, social detachment, loss of freedom, and in the long run, decide future.[17,18] In this manner, drug revelation endeavors expect to increase BMD and decrease the fracture rate.

1.4 Prevention of Osteoporosis

The improvement of bone density during youth and puberty can assist with lessening the risk of having osteoporosis create. Moreover, an eating regimen plentiful in calcium and vitamin D, a solid way of life without smoking or over the top alcohol consumption, and weightbearing exercise all might lessen the risk of osteoporosis. Suitable BMD testing can help the early conclusion of osteopenia and osteoporosis. Standard monthly cycles are fundamental in premenopausal ladies to keep up with bone thickness. Delayed times of amenorrhea can bring about bone misfortune.

2.0 Causes of Osteoporosis

Osteoporosis might be arranged into essential and optional causes. Essential osteoporosis might be partitioned into Type I, postmenopausal osteoporosis, which is related with menopause or estrogen lack, and Type II osteoporosis, age-related or decrepit osteoporosis, which influences people more established than 70 years. Optional causes connective tissue issues, gastrointestinal (GI) problems, nourishment, inflammatory arthropathy, immobilization, hematopoietic issues, constant renal sickness, endocrine problems and incorporate meds.

2.1 Post-menopause and Age

Hormones, like estrogen, parathyroid hormone (PTH) and testosterone assume a huge part in bone renovating by repressing bone breakdown and advancing bone development. The pinnacle bone mass is reached at the age of 25-30 years in ladies. The diminished creation of estrogen in postmenopausal ladies prompts significant bone misfortune. While bone misfortune is advanced during the perimenopausal period, the pace of bone misfortune diminishes quite a while after menopause. Then again, a continuous diminishing in BMD is seen in men. With maturing, sex-hormone restricting globulin is considered to inactivate testosterone and estrogen and might be engaged with the dynamic decay of BMD.[19] Subsequently, because old enough related hormonal changes, people have equivalent paces of bone misfortune by the age of 60 years and are in danger of creating osteoporosis.[20,21] Negative bone revamping in old women is connected with both cortical and cancellous bone, the aggravation of bone microarchitecture besides, bone mishap. Trabecular reducing is seen in cancellous bone, while diminished cortical thickness and extended cortical porosity are seen in cortical bone.[22,23] On the other hand, bone mishap is predominantly associated with reduced bone game plan and low bone turnover in men.

2.2. Secondary Osteoporosis

Glucocorticoids, used to suppress, autoimmune and inflammatory diseases, various allergies and to avoid graft-versus-host disease following transplantation, are the most widely recognized reason for drug-initiated osteoporosis. The drawn-out utilization of glucocorticoids can bring about complexities, for example, glucocorticoid-induced osteoporosis (GIO).[24,25] Glucocorticoids improve the development and differentiation of osteoclasts[26], while restraining osteoblastogenesis by advancing osteoblast and osteocyte apoptosis[27], bringing about expanded bone resorption and diminished bone arrangement.[28,29] Glucocorticoids additionally suppress insulin-like development factor 1 (IGF1), which advances bone arrangement by animating type I collagen blend, prompting collagen debasement and osteoblast apoptosis. In GIO, a quick decay of BMD has been seen inside three to a half year of start of glucocorticoid treatment.[30] Ongoing low-portion glucocorticoid therapy in men getting androgen-hardship treatment for prostate malignant growth has been related with an expanded gamble of osteoporosis and the event of additional breaks, contrasted with control people.[31] Moreover, patients with Cushing's syndrome may

likewise experience the ill effects of sped up bone misfortune because of abundance glucocorticoid creation.[32]

2.3. Heritable Factor on Osteoporotic Fractures

Endeavors have been made to recognize the systems underlying osteoporosis utilizing omics innovations.[33,34] Albeit the ongoing utilitarian genomics and other omics investigations of osteoporosis have constraints, related particularly with the absence of solid human control tests, it is critical to proceed with examinations in this field as the right now utilized demonstrative technique, BMD, can't foresee who will encounter an osteoporotic crack. It is normal that a multi-omics examination will uncover the exact component fundamental osteoporotic breaks and distinguish high-risk patients all the more effectively in the future.[35,36]

For example, it has been exhibited that a missense variation (Gln63Arg) of CNR2, which was unequivocally connected with BMD in a populace of postmenopausal osteoporosis patients, influences cannabinoid receptor type 2 (CB2) expression and movement.[37] In this manner, a diminishing in the articulation or viability of CB2 flagging was recommended to influence lower bone density and even osteoporosis.

3.0. Molecular Mechanism of Bone Remodeling and Osteoporosis

3.1. Role of Bone Cells in Bone Loss

Osteoclasts, osteocytes and osteoblasts are bone cells that are straightforwardly associated with bone redesigning.[38] Bone arrangement, by mesenchymal stem cell (MSC)- determined osteoblasts and bone resorption by tissue-explicit macrophage polykaryons-derived osteoclasts are facilitated to keep up with bone mineral homeostasis and strength. Bone loss can happen because of the breakdown of every cell type.

3.1.1. Osteoclasts

Osteoclasts are enormous multinucleated cells that adhere deep down and resorb it, bringing about the development of openings and the arrival of calcium into the blood. Osteoclasts instigate bone resorption, a course of mineral disintegration and bone debasement, through discharging proteolytic compounds and hydrochloric corrosive.[39,40,41,42] The significant proteolytic catalysts let out of osteoclasts are lysosomal enzymes (e.g., cathepsin K) and matrix metallopeptidase 9 (MMP-9).[43-45] This can happen in light of parathyroid chemical (PTH) and calcitonin excitement. PTH-initiated osteoclasts can deliver minerals back into the circulatory system, as a piece of the instrument of calcium homeostasis.[38] PTH can likewise in a roundabout way increment osteoblast multiplication.

3.1.2. Osteoblast

Osteoblast-induced advancement of new bone starts in the embryo roughly six weeks following fertilization. Bone development can be partitioned into two kinds of solidification: intramembranous and endochondral.[46] The previous includes in a significant cycle happening during the regular healing of fractures and the development of the level bones of the clavicles and skull. Endochondral solidification is an interaction connected with the development of long bones, ligament substitution, and recuperating of bone cracks.[47,48] During intramembranous bone development, MSCs multiply and separate into osteoblasts, which produce bone by orchestrating extracellular framework proteins, like sort I collagen, the most bountiful one. When stored, the extracellular framework is in this manner mineralized through the aggregation of calcium phosphate as hydroxyapatite (Ca10(PO4)6(OH)2).[49]

3.1.3. Osteocyte

Osteocytes definitely stand out enough to be noticed for their focal job in bone redesigning. As one of the major cell parts of bone tissue, osteocytes are totally implanted in the bone framework and contain over 90% of all bone cells.[50]

3.1.4. Adipocyte

Bone marrow adipogenesis assumes a basic part in bone loss related with maturing as well as sicknesses, for example, diabetes mellitus. The separation of adipocytes got from MSC in bone marrow contends with osteoblastogenesis by its temperament of genealogy distribution while the experienced adipocytes express RANKL and advance osteoclastogenesis.[51,52]

Notwithstanding the guideline by record factors in bone cells and adipocytes, paracrine impacts by adipokines, for example, omentin-1, adiponectin, leptin, visfatin, resistin and chemerin secreted from adipocytes have been displayed to include in bone redesigning.

3.2. Other Factors for Osteoporosis

GIO is the most widely recognized type of secondary osteoporosis.[53] A few investigations have exhibited that a persistent glucocorticoid treatment is unequivocally connected with a low BMD and high defenselessness to fractures. Prednisolone treatment instigates apoptosis of osteoblasts and osteocytes, prompting decrease of bone formation.[54] Iron is additionally a significant risk factor for osteoporosis.[55] Iron over-burden is for the most part an outcome of persistent blood bonding's that are fundamental in problems, for example, sickle cell sickliness, genetic hemochromatosis and beta thalassemia major. Iron over-burden in mice brings about expanded oxidative pressure and bone resorption, prompting changes in bone microarchitecture and bone loss. Iron can straightforwardly restrain osteogenic responsibility and bone.

Diagnostic Imaging

Osteoporosis is a clinically quiet sickness until it appears as crack. The most widely recognized destinations of osteoporotic break are the vertebrae, trailed by the distal

lower arm and hip. Demonstrative imaging, for example, X-ray filtering, CT examining, bone outputs and plain radiographs can help the determination of osteoporotic cracks. Two-thirds of all vertebral breaks are clinically quiet, and just might be analyzed utilizing demonstrative imaging. Patients might give grievances of deficiency of level, kyphotic stance without torment, or intense hard agony.

Therapeutic Approach and Novel Strategies

Numerous prescriptions and therapeutic choices have been laid out for the treatment of osteoporosis.[56] As osteoporosis happens because of an irregularity between bone resorption and bone development, the pharmacological choices for its administration are anabolic specialists and anti-resorptive.

4.1. Anti-Resorptive Agents

4.1.1. Bisphosphonates (BPs)

BPs come in close contact with osteoclasts and diminish bone resorption by prompting osteoclast apoptosis. BPs are steady analogs of inorganic pyrophosphate and have a center design of P-C-P bonds, which are liable for the solid restricting fondness toward hydroxyapatite, the significant mineral part of bone.[57] This limiting to bone minerals empowers BPs to be taken up by osteoclasts and restrain their movement. BPs have been utilized for the treatment of osteoporosis since the 1990s. They are accessible in reasonable conventional structure, in oral and intravenous definitions, and stay the first-line prescriptions for the treatment of osteoporosis.[58] Ibandronate and zoledronic corrosive are utilized intravenously while ibandronate, risedronate and alendronate are accessible as oral tablets. BPs are supported for use in GIO patients who are at expanded hazard of crack.[59-61] The major ADR is the risk of abnormal femoral breaks and osteonecrosis of the jaw. Gastrointestinal and renal inconveniences have likewise been accounted for[62,63], and long-haul utilization of BPs is additionally connected with a gamble for osteomalacia.[64] BPs can be recommended for under five years and are enhanced with calcium.

4.1.2. Denosumab

Denosumab (Prolia) is a human IgG2 monoclonal antibody against RANKL that restrains osteoclast development, capability, and endurance.[65-67] The half-existence of denosumab is roughly 26 days and it doesn't seem to neutralizing antibodies.[68] Denosumab is FDA-approved for the therapy of postmenopausal osteoporosis with a high risk for crack as well concerning bone misfortune in men with prostate malignant growth getting androgen hardship treatment. It has additionally been supported for ladies with breast malignant growth, who are in danger for osteoporotic break. A 60 mg dose is applied subcutaneously at regular intervals and can be enhanced with oral calcium and vitamin D. In GIO, denosumab was demonstrated to be more compelling than risedronate in expanding BMD.[69] The ADR of denosumab is connected with the way that RANKL is additionally plentifully communicated by dendritic cells and initiated T lymphocytes, and its adversarial impact could influence the insusceptible framework.[70] In the past review, it was accounted for that the denosumab treatment bunch showed skin dermatitis (3%) and cellulitis (0.3%) contrasted with the benchmark group.[71]

4.1.3. Selective Estrogen Receptor Modulators (SERMs)

Estrogen has been displayed to straightforwardly control the endurance of mature osteoclasts by means of the Fas/FasL framework.[72] Reliably, particular removal of estrogen receptor alpha in the osteoclasts of ladies could prompt an osteoporotic bone-like aggregate. SERM or estrogen collaborates with the RANKL/RANK/OPG framework and diminishes bone resorption.[73] Raloxifene, addressing double agonistic and antagonistic characteristics in estrogenic pathways (estrogen agnonist/antagonist, EAA), is a first-line treatment for patients with a spine crack risk. It can likewise be recommended to patients who have been treated with BPs. A blend of formed estrogens and bazedoxifene was supported by FDA for use in postmenopausal people for the counteraction of osteoporosis and the treatment of moderate-to-extreme vasomotor frameworks.[16] Be that as it may, raloxifene is related with a little expansion in the risk of venous thromboembolism and stroke. Then again, as the general wellbeing chances surpass the advantages, hormonal substitution treatment, like estrogen-progestin treatment, is not generally suggested as first line treatment for the counteraction of osteoporosis in postmenopausal ladies.[74,75]

4.1.4. Calcitonin

Calcitonin is a manufactured polypeptide hormone with the regular properties of calcitonin, which is tracked down in fish, birds and mammals. Calcitonin receptors are communicated on osteoblasts and osteoclasts. Calcitonin keeps osteoclast forerunners from developing and controls osteoclast capability.[76-78] This peptide chemical ties to receptors for the most part situated on the outer layer of osteoclasts, bringing about decrease of bone resorption movement. Moreover, calcitonin has a pain-relieving impact.[79] In this manner, it very well might be a favored treatment for patients with intense osteoporotic cracks. Calcitonin acquired FDA endorsement for the treatment of osteoporosis in postmenopausal ladies who have had osteoporosis for over five years and couldn't get elective medicines. Be that as it may, the calcitonin-salmon nasal splash makes antagonistic impacts, including rhinitis, nasal aggravation, back torment, nosebleed, and cerebral pain.[80]

4.5. Non-Pharmacological Fracture Prevention

4.5.1. Calcium

Intake of calcium is the most ideal choice just in patients whose osteoporosis pathology is directly connected with calcium deficiency or patients with auxiliary hyperparathyroidism. Calcium administration (800-1200

mg day to day) will smother PTH release and in the long run decline bone resorption and bone turnover. Be that as it may, over the top calcium consumption (in excess of 1500 mg absolute day to day) isn't beneficial, will be removed, and it very well may be related with an expanded gamble of renal stones.[81,82]

4.5.2. Vitamin D

Vitamin D regulates calcium digestion, including bone resorption, gastrointestinal absorption and renal excretion. All patients getting glucocorticoid treatment ought to further develop nourishment to diminish fracture risk, and it very well may be to some extent accomplished by satisfactory calcium and vitamin D status (serum level of 25-hydroxyvitamin D, > 20 ng/mL; 50 nmol/L). To address the inadequacies, enhancements can be utilized at a portion of 600-800 IU vitamin D daily. A few reports have shown that dynamic vitamin D has constructive outcomes in expanding BMD and forestalling vertebral breaks.[83,84] Running against the norm, irregular high portions of vitamin D (60,000 IU month to month or 500,000 IU every year) have been related with an expanded risk of falls and breaks. In this manner, the suggested day to day portion shouldn't surpass 4000 IU of vitamin D in ordinary status.[85,86]

4.5.3. Vitamin K2

Vitamin K2 (menaquinone) is considered to help the gamma-carboxylation of osteocalcin, which is delivered by osteoblasts during bone matrix arrangement. It has been accounted for that a high serum level of undercarboxylated osteocalcin is a gamble factor for cracks in older ladies, which could be utilized as a free marker of break. Menatetrenone administration prompts diminished serum levels of undercarboxylated osteocalcin.[87-89]

4.6. Novel Targets, Novel Approach, and Experimental Materials for the Prevention of Osteoporosis

4.6.1. Combination Therapies

Combination treatments with denosumab and estrogen-like medications (e.g., raloxifene) displayed better viability over monotherapy with an extra 36% decrease in fracture risk[90], and a quicker BMD increment and complete recovery of hip BMD[91]; however, protection from break isn't known. Then again, the combination BPs and teriparatide delivers no significant advantage over monotherapy.[92] All things being equal, the consecutive utilization of these medications for achieving long haul the executives of osteoporosis risk is supported. For example, estrogen and raloxifene can be bought into moderately youthful postmenopausal ladies, trailed by teriparatide and abaloparatide, which are suitable for patients at fast approaching gamble of vertebral break. Additionally, with those treatments, continuation of treatment with BPs or denosumab ought to be viewed as in patients with a high gamble of crack.

4.6.1. Stem Cells

Stem cell-based treatments are turning out to be progressively significant in the therapy of persistent and dependable sicknesses, including osteoporosis, as they could empower corrective and customized regenerative medication draws near. A few distinct kinds of stem cells have been assessed to regulate osteoporosis, including embryonic, instigated pluripotent, and MSCs.[93-97] Among them, MSCs are basic possibility for bone regenerative medication, as they enjoy upper hands over different sorts of stem cells clinically, including simplicity of collecting, immunosuppressive results, and less moral worries.[98-100] It has likewise been found that bioactive particles, for example, IL-6, angiogenin, hepatocyte development factor (HGF) and vascular endothelial development factor (VEGF) that are gotten from MSCs, can uphold bone recovery by and large.[101-104] Moreover, exosomes delivered by MSCs have been exhibited to promisingly affect bone redesigning and the counteraction of bone loss in vivo.[105,106]

5.0. CONCLUSIONS

Osteoporosis is an undeniably predominant condition as the maturing populace develops quick all around the world. It causes more than 8.9 million breaks each year overall.[107] In western nations, yet additionally in East Asian nations, like China, Korea, and Japan, numerous older ladies and men as of now have expanded osteoporotic crack dangers. Osteoporotic cracks might prompt critical utilitarian restrictions and expanded mortality. Hence, an opportune determination, solution of prescription, as well as the administration of this sickness are significant. The fitting beginning stage for therapy is disputable in the clinical administration of osteoporosis. In postmenopausal ladies it is difficult to demonstrate that there is fracture assurance for the people with osteopenia on account of the trouble in recognizing low quality bone. With the numerous choices, a far reaching, careful interdisciplinary methodology can assist with enhancing the treatment, and thusly, work on useful results and personal satisfaction for patients with osteoporosis. The extent of the issue of osteoporosis requires close thoughtfulness regarding the fitting treatment of patients with osteoporosis either by the orthopedist, physiatrist, or other doctor.

6.0. REFERENCES

1. Genant, H.K.; Cooper, C.; Poor, G.; Reid, I.; Ehrlich, G.; Kanis, J.; Nordin, B.C.; Barrett-Connor, E.; Black, D.; Bonjour, J. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos. Int., 1999; 10: 259–264.
2. Todd, J.; Robinson, R. Osteoporosis and exercise. Postgrad. Med. J., 2003; 79: 320–323.
3. Bawa, S. The significance of soy protein and soy bioactive compounds in the prophylaxis and treatment of osteoporosis. J. Osteoporos, 2010, 2010.

4. Wright, N.C.; Looker, A.C.; Saag, K.G.; Curtis, J.R.; Delzell, E.S.; Randall, S.; Dawson–Hughes, B. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J. Bone. Min. Res., 2014; 29: 2520–2526.
5. Sözen, T.; Özı¸sık, L.; Ba¸saran, N.Ç. An overview and management of osteoporosis. Eur. J. Rheumatol, 2017; 4: 46–56.
6. Lindsay R, Silverman SL, Cooper C, et al: Risk of new vertebral fracture in the year following a fracture. JAMA, 2001; 285: 320–323.
7. Lane JM, Riley EH, Wirganowicz PZ: Osteoporosis: Diagnosis and treatment. Instr Course Lect, 1997; 46: 445–458.
8. Genant HK, Cooper C, Poor G, et al: Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int., 1999; 10: 259–264.
9. Cummings SR, Black DM, Nevitt MC, et al: Bone density at various sites for prediction of hip fractures: The Study of Osteoporotic Fractures Research Group. Lancet, 1993; 341: 72–75.
10. Group, W.S. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser., **1994;** 843: 1–129.
11. Schuit, S.; Van der Klift, M.; Weel, A.; De Laet, C.; Burger, H.; Seeman, E.; Hofman, A.; Uitterlinden, A.; Van Leeuwen, J.; Pols, H. Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone, **2004;** 34: 195–202.
12. Compston, J.E.; McClung, M.R.; Leslie, W.D. Osteoporosis. Lancet, **2019;** 393: 364–376.
13. Cauley, J.; Thompson, D.; Ensrud, K.; Scott, J.; Black, D. Risk of mortality following clinical fractures. Osteoporos. Int., **2000;** 11: 556–561.
14. Morin, S.; Lix, L.; Azimaee, M.; Metge, C.; Caetano, P.; Leslie, W. Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos. Int., **2011;** 22: 2439–2448.
15. Abrahamsen, B.; Van Staa, T.; Ariely, R.; Olson, M.; Cooper, C. Excess mortality following hip fracture: A systematic epidemiological review. Osteoporos. Int., **2009;** 20: 1633–1650.
16. Cosman, F.; de Beur, S.J.; LeBo_, M.; Lewiecki, E.; Tanner, B.; Randall, S.; Lindsay, R. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos. Int., **2014;** 25: 2359–2381.
17. Inacio, M.C.;Weiss, J.M.; Miric, A.; Hunt, J.J.; Zohman, G.L.; Paxton, E.W. A community-based hip fracture registry: Population, methods, and outcomes. Perm. J., **2015;** 19: 29–36.
18. Bentler, S.E.; Liu, L.; Obrizan, M.; Cook, E.A.; Wright, K.B.; Geweke, J.F.; Chrischilles, E.A.; Pavlik, C.E.; Wallace, R.B.; Ohsfeldt, R.L. The aftermath of hip fracture: Discharge placement, functional status change, and mortality. Am. J. Epidemiol, **2009;** 170: 1290–1299.
19. Hunter, D.J.; Sambrook, P.N. Bone loss: Epidemiology of bone loss. Arthritis Res., **2000;** 2: 1–5.
20. Raisz, L.G. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J. Clin. Investig, **2005;** 115: 3318–3325.
21. Lin, J.T.; Lane, J.M. Osteoporosis: A review. Clin. Orthop. Relat. Res., **2004;** 425: 126–134.
22. Parfitt, A.; Mathews, C.; Villanueva, A.; Kleerekoper, M.; Frame, B.; Rao, D. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J. Clin. Investig. **1983;** 72: 1396–1409.
23. Zebaze, R.M.; Ghasem-Zadeh, A.; Bohte, A.; Iuliano-Burns, S.; Mirams, M.; Price, R.I.; Mackie, E.J.; Seeman, E. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: A cross-sectional study. Lancet, **2010;** 375: 1729–1736.
24. Fardet, L.; Petersen, I.; Nazareth, I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology, **2011;** 50: 1982–1990.
25. Compston, J. Glucocorticoid-induced osteoporosis: An update. Endocrine, **2018;** 61: 7–16.
26. Weinstein, R.S.; Jilka, R.L.; Parfitt, A.M.; Manolagas, S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Investig, **1998;** 102: 274–282.
27. Wang, L.; Heckmann, B.L.; Yang, X.; Long, H. Osteoblast autophagy in glucocorticoid–induced osteoporosis. J. Cell. Physiol, **2019;** 234: 3207–3215.
28. Den Uyl, D.; Bultink, I.E.; Lems, W.F. Advances in glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep., **2011;** 13: 233–240.
29. Chotiyarnwong, P.; McCloskey, E.V. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat. Rev. Endocrinol, **2020;** 16: 1–11.
30. Buckley, L.; Guyatt, G.; Fink, H.A.; Cannon, M.; Grossman, J.; Hansen, K.E.; Humphrey, M.B.; Lane, N.E.; Magrey, M.; Miller, M. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid–induced osteoporosis. Arthritis Rheumatol, **2017;** 69: 1521–1537.
31. Shahinian, V.B.; Kuo, Y.-F.; Freeman, J.L.; Goodwin, J.S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med., **2005;** 352: 154–164.
32. Kawamata, A.; Iihara, M.; Okamoto, T.; Obara, T. Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: Prospective study. World J. Surg, **2008;** 32: 890–896.

33. Yang, T.-L.; Shen, H.; Liu, A.; Dong, S.-S.; Zhang, L.; Deng, F.-Y.; Zhao, Q.; Deng, H.-W. A road map for understanding molecular and genetic determinants of osteoporosis. Nat. Rev. Endocrinol, **2019;** 16: 91–103.
34. Morris, J.A.; Kemp, J.P.; Youlten, S.E.; Laurent, L.; Logan, J.G.; Chai, R.C.; Vulpescu, N.A.; Forgetta, V.; Kleinman, A.; Mohanty, S.T. An atlas of genetic influences on osteoporosis in humans and mice. Nat. Genet, **2019;** 51: 258–266.
35. Sun, Y.V.; Hu, Y.-J. Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases. In Advances in Genetics; Elsevier: Amsterdam, The Netherlands, 2016; 93: 147–190.
36. Hasin, Y.; Seldin, M.; Lusis, A. Multi-omics approaches to disease. Genome Biol., **2017;** 18: 83.
37. Karsak, M.; Cohen-Solal, M.; Freudenberg, J.; Ostertag, A.; Morieux, C.; Kornak, U.; Essig, J.; Erxlebe, E.;Bab, I.; Kubisch, C. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol.Genet, **2005;** 14: 3389–3396.
38. Boyle, W.J.; Simonet, W.S.; Lacey, D.L. Osteoclast di_erentiation and activation. Nature, **2003;** 423: 337–342.
39. Xu, F.; Teitelbaum, S.L. Osteoclasts: New insights. Bone Res., **2013;** 1: 11–26.
40. Teitelbaum, S.L. Bone resorption by osteoclasts. Science, **2000;** 289: 1504–1508.
41. Hienz, S.A.; Paliwal, S.; Ivanovski, S. Mechanisms of bone resorption in periodontitis. J. Immunol. Res., **2015;** 2015: 615486.
42. Rucci, N. Molecular biology of bone remodelling. Clin. Cases Min. Bone Metab., **2008;** 5: 49–56.
43. Dong, Z.; Bonfil, R.D.; Chinni, S.; Deng, X.; Trindade Filho, J.C.; Bernardo, M.; Vaishampayan, U.; Che, M.; Sloane, B.F.; Sheng, S. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am. J. Pathol., **2005;** 166: 1173–1186.
44. Henriksen, K.; Bollerslev, J.; Everts, V.; Karsdal, M. Osteoclast activity and subtypes as a function of physiology and pathology-Implications for future treatments of osteoporosis. Endocr. Rev., **2011;** 32: 31–63.
45. Das, S.; Crockett, J.C. Osteoporosis–a current view of pharmacological prevention and treatment. Drug. Des. Devel, **2013;** 7: 435–448.
46. Nakashima, K.; de Crombrugghe, B. Transcriptional mechanisms in osteoblast di_erentiation and bone formation. Trends Genet, **2003;** 19: 458–466.
47. BRIGHTON, C.T.; Sugioka, Y.; HUNT, R.M. Cytoplasmic structures of epiphyseal plate chondrocytes: Quantitative evaluation using electron micrographs of rat costochondral junctions with special reference to the fate of hypertrophic cells. J. Bone Jt. Surg. Am., **1973;** 55: 771–784.
48. De Crombrugghe, B.; Lefebvre, V.; Nakashima, K. Regulatory mechanisms in the pathways of cartilage and bone formation. Curr. Opin. Cell Biol., **2001;** 13: 721–728.
49. Long, F. Building strong bones: Molecular regulation of the osteoblast lineage. Nat. Rev. Mol. Cell Biol., **2012;** 13: 27–38.
50. Tate, M.L.K.; Adamson, J.R.; Tami, A.E.; Bauer, T.W. The osteocyte. Int. J. Biochem. Cell Biol., **2004;** 36: 1–8.
51. Muruganandan, S.; Ionescu, A.M.; Sinal, C.J. At the Crossroads of the Adipocyte and Osteoclast Di_erentiation Programs: Future Therapeutic Perspectives. Int. J. Mol. Sci., **2020;** 21: 2277.
52. Takeshita, S.; Fumoto, T.; Naoe, Y.; Ikeda, K. Age-related marrow adipogenesis is linked to increased expression of RANKL. J. Biol. Chem., **2014;** 289: 16699–16710.
53. Whittier, X.; Saag, K.G. Glucocorticoid-induced osteoporosis. Rheum. Dis. Clin. North. Am., **2015;** 42: 177–189.
54. Migliaccio, S.; Brama, M.; Fornari, R.; Greco, E.A.; Spera, G.; Malavolta, N. Glucocorticoid-induced osteoporosis: An osteoblastic disease. Aging Clin. Exp. Res., **2007;** 19: 5–10.
55. Tsay, J.; Yang, Z.; Ross, F.P.; Cunningham-Rundles, S.; Lin, H.; Coleman, R.; Mayer-Kuckuk, P.; Doty, S.B.; Grady, R.W.; Giardina, P.J. Bone loss caused by iron overload in a murine model: Importance of oxidative stress. Blood, **2010;** 116: 2582–2589.
56. Ukon, Y.; Makino, T.; Kodama, J.; Tsukazaki, H.; Tateiwa, D.; Yoshikawa, H.; Kaito, T. Molecular-based treatment strategies for osteoporosis: A literature review. Int. J. Mol. Sci., **2019;** 20: 2557.
57. Russell, R.G.G. Bisphosphonates: The first 40 years. Bone, **2011;** 49: 2–19.
58. Crandall, C.J.; Newberry, S.J.; Diamant, A.; Lim, Y.-W.; Gellad,W.F.; Booth, M.J.; Motala, A.; Shekelle, P.G. Comparative e_ectiveness of pharmacologic treatments to prevent fractures: An updated systematic review. Ann. Int. Med., **2014;** 161: 711–723.
59. Saag, K.G.; Emkey, R.; Schnitzer, T.J.; Brown, J.P.; Hawkins, F.; Goemaere, S.; Thamsborg, G.; Liberman, U.A.; Delmas, P.D.; Malice, M.-P. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Eng. J. Med., **1998;** 339: 292–299.
60. Reid, D.M.; Hughes, R.A.; Laan, R.F.; Sacco–Gibson, N.A.; Wenderoth, D.H.; Adami, S.; Eusebio, R.A.; Devogelaer, J.P. Efficacy and safety of daily risedronate in the treatment of corticosteroid–induced osteoporosis in men and women: A randomized trial. J. Bone Min. Res., **2000;** 15: 1006–1013.
61. Reid, D.M.; Devogelaer, J.-P.; Saag, K.; Roux, C.; Lau, C.-S.; Reginster, J.-Y.; Papanastasiou, P.; Ferreira, A.; Hartl, F.; Fashola, T. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy,

randomised controlled trial. Lancet, **2009;** 373: 1253–1263.
62. Zhou, J.; Ma, X.;Wang, T.; Zhai, S. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: A systematic review with network meta-analyses. Osteoporos. Int., **2016;** 27: 3289–3300.
63. Zhou, J.; Wang, T.; Zhao, X.; Miller, D.R.; Zhai, S. Comparative efficacy of bisphosphonates to prevent fracture in men with osteoporosis: A systematic review with network meta-analyses. Rheumatol. Ther., **2016;** 3: 117–128.
64. Hoppé, E.; Masson, C.; La_tte, A.; Chappard, D.; Audran, M. Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate. Morphologie, **2012;** 96: 40–43.
65. Lin, T.;Wang, C.; Cai, X.Z.; Zhao, X.; Shi, M.M.; Ying, Z.M.; Yuan, F.Z.; Guo, C.; Yan, S.G. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: A meta–analysis. Int. J. Clin. Pr., **2012;** 66: 399–408.
66. Von Keyserlingk, C.; Hopkins, R.; Anastasilakis, A.; Toulis, K.; Goeree, R.; Tarride, J.-E.; Xie, F. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: A meta-analysis. Semin. Arthritis Rheum, **2011;** 41: 178–186.
67. Cummings, S.R.; Martin, J.S.; McClung, M.R.; Siris, E.S.; Eastell, R.; Reid, I.R.; Delmas, P.; Zoog, H.B.; Austin, M.; Wang, A. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Eng. J. Med., **2009;** 361: 756–765.
68. Hanley, D.; Adachi, J.; Bell, A.; Brown, V. Denosumab: Mechanism of action and clinical outcomes. Int. J. Clin. Pr., **2012;** 66: 1139–1146.
69. Saag, K.G.; Wagman, R.B.; Geusens, P.; Adachi, J.D.; Messina, O.D.; Emkey, R.; Chapurlat, R.; Wang, A.; Pannacciulli, N.; Lems, W.F. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: Amulticentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endo, **2018;** 6: 445–454.
70. Walsh, M.C.; Choi, Y. Biology of the RANKL–RANK–OPG system in immunity, bone, and beyond. Front. Immunol, **2014;** 5: 511.
71. Anastasilakis, A.D.; Toulis, K.A.; Polyzos, S.A.; Anastasilakis, C.D.; Makras, P. Long-term treatment of osteoporosis: Safety and efficacy appraisal of denosumab. Clin. Risk Manag, **2012;** 8: 295–306.
72. Nakamura, T.; Imai, Y.; Matsumoto, T.; Sato, S.; Takeuchi, K.; Igarashi, K.; Harada, Y.; Azuma, Y.; Krust, A.; Yamamoto, Y. Estrogen prevents bone loss via estrogen receptor _ and induction of Fas ligand in osteoclasts. Cell, **2007;** 130: 811–823.
73. Ettinger, B.; Black, D.M.; Mitlak, B.H.; Knickerbocker, R.K.; Nickelsen, T.; Genant, H.K.; Christiansen, C.; Delmas, P.D.; Zanchetta, J.R.; Stakkestad, J. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA, **1999;** 282: 637–645.
74. Watts, N.B.; Adler, R.A.; Bilezikian, J.P.; Drake, M.T.; Eastell, R.; Orwoll, E.S.; Finkelstein, J.S. Osteoporosis in men: An Endocrine Society clinical practice guideline. J. Clin. Endocr. Metab, **2012;** 97: 1802–1822.
75. Tu, K.N.; Lie, J.D.; Wan, C.K.V.; Cameron, M.; Austel, A.G.; Nguyen, J.K.; Van, K.; Hyun, D. Osteoporosis: A review of treatment options. Pharm. Ther., **2018;** 43: 92.
76. Binkley, N.; Bolognese, M.; Sidorowicz–Bialynicka, A.; Vally, T.; Trout, R.; Miller, C.; Buben, C.E.; Gilligan, J.P.; Krause, D.S.; Investigators, O.C.i.P.O. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J. Bone Min. Res., **2012;** 27: 1821–1829.
77. Ishida, Y.; Kawai, S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am. J. Med., **2004;** 117: 549–555.
78. Muñoz-Torres, M.; Alonso, G.; Raya, P.M. Calcitonin therapy in osteoporosis. Treat. Endocrinol, **2004;** 3: 117–132.
79. Ito, A.; Takeda, M.; Yoshimura, T.; Komatsu, T.; Ohno, T.; Kuriyama, H.; Matsuda, A.; Yoshimura, M. Anti-hyperalgesic e_ects of calcitonin on neuropathic pain interacting with its peripheral receptors. Mol. Pain, **2012;** 8: 42.
80. Trovas, G.; Lyritis, G.; Galanos, A.; Raptou, P.; Constantelou, E. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: E_ects on bone mineral density and bone markers. J. Bone Min. Res., **2002;** 17: 521–527.
81. Jackson, R.D.; LaCroix, A.Z.; Gass, M.;Wallace, R.B.; Robbins, J.; Lewis, C.E.; Bassford, T.; Beresford, S.A.; Black, H.R.; Blanchette, P. Calcium plus vitamin D supplementation and the risk of fractures. N. Eng. J. Med., **2006;** 354: 669–683.
82. Bolland, M.J.; Grey, A.; Avenell, A.; Gamble, G.D.; Reid, I.R. Calcium supplements with or without vitamin D and risk of cardiovascular events: Reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ, **2011;** 342: d2040.
83. O'Donnell, S.; Moher, D.; Thomas, K.; Hanley, D.A.; Cranney, A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J. Bone Min. Res., **2008;** 26: 531–542.
84. Papadimitropoulos, E.; Wells, G.; Shea, B.; Gillespie, W.; Weaver, B.; Zytaruk, N.; Cranney, A.; Adachi, J.; Tugwell, P.; Josse, R. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment

in preventing osteoporosis in postmenopausal women. Endocr. Rev., **2002;** 23: 560–569.
85. Sanders, K.M.; Stuart, A.L.; Williamson, E.J.; Simpson, J.A.; Kotowicz, M.A.; Young, D.; Nicholson, G.C. Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. JAMA, **2010;** 303: 1815–1822.
86. Bischo_-Ferrari, H.A.; Dawson-Hughes, B.; Orav, E.J.; Staehelin, H.B.; Meyer, O.W.; Theiler, R.; Dick, W.; Willett,W.C.; Egli, A. Monthly high-dose vitamin D treatment for the prevention of functional decline: A randomized clinical trial. JAMA Intern. Med., **2016;** 176: 175–183.
87. Booth, S.L.; Tucker, K.L.; Chen, H.; Hannan, M.T.; Gagnon, D.R.; Cupples, L.A.;Wilson, P.W.; Ordovas, J.; Schaefer, E.J.; Dawson-Hughes, B. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am. J. Clin. Nutr., **2000;** 71: 1201–1208.
88. Shiraki, M.; Yamazaki, Y.; Shiraki, Y.; Hosoi, T.; Tsugawa, N.; Okano, T. High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment. J. Bone Min. Metab, **2010;** 28: 578–584.
89. Shiraki, M.; Itabashi, A. Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: A randomized prospective study. J. Bone Min. Metab, **2009**, 27: 333–340.
90. Lou, S.; Lv, H.; Yin, P.; Li, Z.; Tang, P.; Wang, Y. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: A systematic review and meta-analysis of randomized controlled trials. Osteoporos. Int., **2019;** 30: 59–70.
91. Kitaguchi, K.; Kashii, M.; Ebina, K.; Kaito, T.; Okada, R.; Makino, T.; Noguchi, T.; Ishimoto, T.; Nakano, T.; Yoshikawa, H. E_ects of single or combination therapy of teriparatide and anti-RANKL monoclonal antibody on bone defect regeneration in mice. Bone, **2018;** 106: 1–10.
92. McClung, M.R. Using osteoporosis therapies in combination. Curr. Osteoporos. Rep., **2017;** 15: 343–352.
93. Li, F.; Zhou, C.; Xu, L.; Tao, S.; Zhao, J.; Gu, Q. E_ect of stem cell therapy on bone mineral density: A meta-analysis of preclinical studies in animal models of osteoporosis. PLoS ONE, **2016;** 11: e0149400.
94. Ilic, D.; Miere, C.; Lazic, E. Umbilical cord blood stem cells: Clinical trials in non-hematological disorders. Br. Med. Bull., **2012;** 102: 43–57.
95. Dzobo, K.; Thomford, N.E.; Senthebane, D.A.; Shipanga, H.; Rowe, A.; Dandara, C.; Pillay, M.; Motaung, K.S.C.M. Advances in regenerative medicine and tissue engineering: Innovation and transformation of medicine. Stem Cells Int., **2018;** 2018: 2495848.
96. Paspaliaris, V.; Kolios, G. Stem cells in osteoporosis: From biology to new therapeutic approaches. Stem Cells Int., **2019;** 2019: 1730978.
97. Goodarzi, P.; Payab, M.; Alavi-Moghadam, S.; Larijani, B.; Rahim, F.; Bana, N.; Sarvari, M.; Adibi, H.; Heravani, N.F.; Hadavandkhani, M. Development and validation of Alzheimer's disease animal model for the purpose of regenerative medicine. Cell Tissue Bank, **2019;** 20: 141–151.
98. Aghebati–Maleki, L.; Dolati, S.; Zandi, R.; Fotouhi, A.; Ahmadi, M.; Aghebati, A.; Nouri, M.; Kazem Shakouri, S.; Yousefi, M. Prospect of mesenchymal stem cells in therapy of osteoporosis: A review. J. Cell. Physiol, **2019;** 234: 8570–8578.
99. Bianco, P.; Cao, X.; Frenette, P.S.; Mao, J.J.; Robey, P.G.; Simmons, P.J.; Wang, C.-Y. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat. Med., **2013;** 19: 35–42.
100. Su, P.; Tian, Y.; Yang, C.; Ma, X.;Wang, X.; Pei, J.; Qian, A. Mesenchymal stem cell migration during bone formation and bone diseases therapy. Int. J. Mol. Sci., **2018;** 19: 2343.
101. Xiao, L.; Sobue, T.; Esliger, A.; Kronenberg, M.S.; Co_n, J.D.; Doetschman, T.; Hurley, M.M. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone, **2010;** 47: 360–370.
102. Ugarte, F.; Ryser, M.; Thieme, S.; Fierro, F.A.; Navratiel, K.; Bornhäuser, M.; Brenner, S. Notch signaling enhances osteogenic di_erentiation while inhibiting adipogenesis in primary human bone marrow stromal cells. Exp. Hematol, **2009;** 37: 867–875.
103. Byun, M.R.; Jeong, H.; Bae, S.J.; Kim, A.R.; Hwang, E.S.; Hong, J.-H. TAZ is required for the osteogenic and anti-adipogenic activities of kaempferol. Bone, **2012;** 50: 364–372.
104. James, A.W. Review of signaling pathways governing MSC osteogenic and adipogenic di_erentiation. Scientifica, **2013;** 2013: 684736.
105. Chu, C.;Wei, S.;Wang, Y.;Wang, Y.; Man, Y.; Qu, Y. Extracellular vesicle and mesenchymal stem cells in bone regeneration: Recent progress and perspectives. J. Biomed. Mater. Res. Part A., **2019;** 107: 243–250.
106. Behera, J.; Tyagi, N. Exosomes: Mediators of bone diseases, protection, and therapeutics potential. Oncoscience, **2018;** 5: 181.
107. Johnell, O.; Kanis, J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int., **2006;** 17: 1726–1733.